GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PuraPharm Corporation Ltd (HKSE:01498) » Definitions » 3-Year FCF Growth Rate

PuraPharm (HKSE:01498) 3-Year FCF Growth Rate : 0.00% (As of Dec. 2024)


View and export this data going back to 2015. Start your Free Trial

What is PuraPharm 3-Year FCF Growth Rate?

PuraPharm's Free Cash Flow per Share for the six months ended in Dec. 2024 was HK$0.12.

During the past 12 months, PuraPharm's average Free Cash Flow per Share Growth Rate was 51.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 11 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of PuraPharm was 13.70% per year. The lowest was 8.00% per year. And the median was 10.85% per year.


Competitive Comparison of PuraPharm's 3-Year FCF Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, PuraPharm's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PuraPharm's 3-Year FCF Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PuraPharm's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where PuraPharm's 3-Year FCF Growth Rate falls into.


;
;

PuraPharm 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


PuraPharm  (HKSE:01498) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


PuraPharm 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of PuraPharm's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


PuraPharm Business Description

Traded in Other Exchanges
N/A
Address
Wireless Centre, Phase One, Unit 201-207, 2nd Floor, Hong Kong Science Park, Tai Po, New Territories, Hong Kong, HKG
PuraPharm Corporation Ltd is a Hong Kong-based Chinese medicine Company. It is engaged in the research and development, production, marketing, and sale of concentrated Chinese medicine granules (CCMG) products marketed under the brand Nong's. The organization provides Chinese medical diagnostic services and operates through several segments: China CCMG, Hong Kong CCMG, Chinese healthcare products, Plantation, and Clinics. The majority of its revenue comes from the Hong Kong CCMG segment, which mainly involves the sale of CCMG products, excluding sales through self-operated clinics in Hong Kong. The group derives revenue from customers located in Hong Kong, Mainland China, and Other countries.
Executives
Chan Yu Ling, Abraham 2101 Beneficial owner
Man Yee Wai, Viola 2202 Interest of your spouse
Fullgold Development Limited 2101 Beneficial owner

PuraPharm Headlines

No Headlines